SCHEMBL14925354

SCHEMBL14925354

CC(=O)c1ccc(-c2ccccc2C(F)(F)F)c(O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.51
AKR1C3 P42330 3/20 0.49
AKR1C2 P52895 3/20 0.49
S100A4 P26447 1/20 0.49
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
KIF11 P52732 1/20 0.44
CRHR1 P34998 1/20 0.43
KMT2A Q03164 1/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
CYP1A2 P05177 1/20 0.41
TSHR P16473 1/20 0.41
KMO O15229 1/20 0.40
PTPRC P08575 1/20 0.40
GPBAR1 Q8TDU6 1/20 0.40
HSD17B1 P14061 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14925368 0.86 PDK2 (0.50) PDK2AKR1C3AKR1C2S100A4MAOA
SCHEMBL10035088 0.86 ALDH1A1 (0.49) PDK2AKR1C3AKR1C2KMT2AMAPT
SCHEMBL14925362 0.84 MAOA (0.49) PDK2AKR1C3AKR1C2S100A4MAOA
SCHEMBL536257 0.84 NOTUM (0.55) PDK2AKR1C3AKR1C2KMT2AMAPT
SCHEMBL14925355 0.82 AKR1C3 (0.52) PDK2AKR1C3AKR1C2S100A4MAOA
SCHEMBL14925366 0.81 MAOA (0.47) PDK2AKR1C3AKR1C2S100A4MAOA
SCHEMBL15746963 0.81 KIF11 (0.53) PDK2AKR1C3AKR1C2S100A4MAOA
SCHEMBL24445837 0.80 KIF11 (0.56) PDK2AKR1C3AKR1C2MAOAMAOB
SCHEMBL881323 0.79 MAPT (0.59) S100A4KMT2ANPC1MAPTRAB9A
SCHEMBL7466543 0.79 KIF11 (0.55) PDK2AKR1C3AKR1C2MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130116227-A1 BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116227-A1 BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF MC2R, NR3C2, REN PDK2 2772/4885AKR1C3 99/4885AKR1C2 131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.